PITTSBURGH and NESS ZIONA, Israel, Aug. 7, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Mapi Pharma Ltd., a fully integrated, late-stage clinical development ...
Meeting program to feature latest clinical findings for GA Depot and showcase commitment to improving care for people living with multiple sclerosis (MS) PITTSBURGH, April 24, 2023 /PRNewswire/ -- ...
NESS ZIONA, Israel, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company focused on introducing innovative long-acting depot ...
Viatris likely just lost one of its top product debuts for 2024, thanks to an FDA rejection of its partner Mapi Pharma’s application for a new version of Teva’s multiple sclerosis (MS) drug Copaxone.
(Reuters) -The U.S. FDA has declined to approve Viatris and Mapi Pharma's once-a-month injection for treating relapsing forms of debilitating neurological condition multiple sclerosis (MS), the ...
Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
PITTSBURGH, April 24, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Mapi Pharma today announced that recent data from ongoing studies of GA Depot 40 mg will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback